A clinical view on the possibility and feasibility of using decamethoxin during the COVID-19 pandemic


  • Oleksandr Halushko Shupyk National Medical Academy of Postgraduate Education, Kyiv




decamethoxine, viral infection, virucidal action, COVID-19


Background. Due to the significant spread of the COVID-19 pandemic and the available contact route of transmission, there is a growing interest in the possibility of using antiseptics to prevent contagion of this viral disease. However, the list of antiseptic drugs for local application is limited.

The aim: to investigate the possibility and feasibility of clinical use of decamethoxine as an antiseptic during the infectious COVID-19 pandemic.

Materials and methods. Researches and systematic reviews published between 2001 and 2020 were studied using PubMed and Google Scholar searches.

Results. It is shown that decamethoxine is an active antiseptic drug, the clinical effectiveness of which has been proven in patients with various pathologies (including bronchial and pulmonary diseases). Decamethoxine can be used in various ways, that provides a variety of routes to deliver the drug to the patient, and it has a strong antiviral activity against different groups of viruses.

Conclusions. The analysis demonstrates the feasibility of using decamethoxine solutions to prevent the occurrence and spread of COVID-19 infection.


Download data is not yet available.


World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020. Geneva, Switzerland: World Health Organization; 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefingon-covid-19---11-march-2020.

Coronavirus in Ukraine. Available from: https://index.minfin.com.ua/ua/reference/coronavirus/ukraine

Use of drugs in COVID-19. Special project of the State Expert Center of the Ministry of Health Ukraine. Available from: http://covid19.dec.gov.ua

Feshchenko YI, Humeniuk MI. The antiseptic drug dekasane in the prevention and treatment of local purulent-inflammatory lesions [Antyseptychnyi preparat dekasan u profilaktytsi ta likuvanni mistsevykh hniino-zapalnykh urazhen] . Ukr. chemotherapeutic journal; 2010; 1(13):65. [In Ukrainian]

Kovalenko SV, Kushnir LD. Experience of application of non-bulazer therapy of aceticysteine (ingamist) in exacerbations of chronic bronchitis in conditions of pulmonologologologist.. Bukovinian Medical Herald [Internet]. Higher State Educational Establishment of Ukraine Bukovinian State Medical University; 2016 Jun 30;20(2 (78)):232–4. Available from: https://doi.org/10.24061/2413-0737.xx.2.78.2016.114 [In Ukrainian]

Panchuk SI, Humeniuk MI, Trokhimenko OP, Dzyublyk IV. Virulicidal action of decamethoxin in relation to viral triggers of infectious exacerbation of bronchial asthma [Virulitsydna diia dekametoksynu po vidnoshenniu do virusnykh tryheriv infektsiinoho zahostrennia bronkhialnoi astmy]. Ukrainian Journal of Pulmonology. 2014;2:48-51. [In Ukrainian]

Paliy VG, Moroz VM, Sobolev VO, Safronov KM, Zheliba MD, Gumenyuk MI. Antimicrobial drug decasan: strategy and tactics for the prevention and treatment of purulent-inflammatory diseases [Antymikrobnyi likarskyi preparat dekasan: stratehiia i taktyka zastosuvannia dlia profilaktyky ta likuvannia hniino-zapalnykh zakhvoriuvan]. Bulletin of Vinnytsia State Medical University, 2004;8(2):449-452. [In Ukrainian]

Konovalov EP, Terletskiĭ VN, Pliatsok AA, Gumeniuk NI, Padiĭ VI, Iakovlev BF. Application of the Decasan at the practice of urgent surgery [Ispol'zovanie antiseptika dekasana v praktike neotlozhnoĭ khirurgii]. Klin Khir. 2004;(9):18-20. [In Russian]

Ivanova M, Mochalov I, Brekhlichuk P, Heley V, Martynchuk O. Study of sensitivity to anti-microbial agents of micro-organisms from zone of purulent inflammation among patients of maxillofacial hospital department. Georgian Med News. 2019 Dec;(297):57-63.

Nazarchuk OA, Chereshniuk IL, Nazarchuk HH. The research of antimicrobial efficacy of antiseptics decamethoxin, miramistin and their effect on nuclear dna fragmentation and epithelial cell cycle. Wiadomości Lekarskie [Internet]. ALUNA; 2019;72(3):374–80. Available from: https://doi.org/10.36740/wlek201903111

Fuss J, Palii V, Voloboyeva A. Evaluating the Effectivenes of Antiseptic Solution Decasan in Treatment of Necrotic Soft Tisue Diseases. Polish Journal of Surgery [Internet]. Index Copernicus; 2016 Jan 1;88(5). Available from: https://doi.org/10.1515/pjs-2016-0058

Nazarchuk OA. Аntiseptics: modern strategy of struggle with causing agents of the іnfection complications. Klin Khir. 2016;(9):59-61. [In Ukrainian]

Arseniuk VV, Bartosh AM, Vasul'ianov DS, Voĭtenko II, Hryniv OV, Smotrov MI. Probability of incidence of abdominal adhesional process in peritonitis, depending on the sanation preparation applied. Klin Khir. 2014 Dec;(12):78. [In Ukrainian]

Nazirov FN, Aripova NU, Makhkamova MN, Dzhamalov SI, Pulatov MM, Magzumov IKh, Isroilov BN. Use of antiseptic dekasan in complex treatment of peritonitis. Klin Khir. 2014 Jan;(1):26-7. [In Russian]

Aripova NU, Magzumov IKh. Sanation of biliary system using antiseptic decasan in complex treatment of cholangitis. Klin Khir. 2014 Feb;(2):20-2. [In Russian]

Nazarchuk OA, Vernyhorods'kyĭ SV, Paliĭ VH, Nazarchuk HH, Paliĭ DV, Honchar OO, Zadereĭ NV. Local impact of antiseptic medical textile on tissues of organism. Klin Khir. 2013 Jul;(7):61-4. [In Ukrainian]

Shomirov AK, Khairutdinov NH, Rakhmanov UM, Mordukhaev SL, Yuldashev SK Efficacy of decasan in the treatment of infected wounds in obstetrics and gynecology. Ukrainian Chemotherapeutic Journal, 2012;1-2(25):86-90. [In Ukrainian]

Boĭko VV, Lohachev VK, Tymchenko MIe. Application of decamethoxin solution in the treatment of surgical peritonitis. Klin Khir. 2012 Dec;(12):16-9. [In Ukrainian]

Zakharash MP, Kucher ND, Krivoruk MI, Iaremchuk IA. Application of antiseptic decasan in purulent infections of pararectal region. Klin Khir. 2011 Apr;(4):18-20. [In Russian]

Nichitailo ME. Dekasan application in treatment of infected pancreatic necrosis and its complications. Klin Khir. 2010 Mar;(3):50-1. [In Russian]

Fomin PD, Lissov AI, Kozlov SN, Mikhal'chishin SN. Application of antiseptic dekasan in urgent abdominal surgery. Klin Khir. 2009 Nov-Dec;(11-12):98-100. [In Russian]

Gumeniuk, MI, Opimakh SG, Gumeniuk GL, Ignatieva VI. Decamethoxine: the option in treatment of patients with asthma infectious exacerbations. Ukrainian Pulmonology Journal [Internet]. Ukrainian Pulmonology Journal; 2019;104(2):25–32. Available from: https://doi.org/10.31215/2306-4927-2019-104-2-25-32

Shkurupii D. Prevention of ventilator-associated pneumonia in newborns. Wiad Lek. 2018;71(4):821-823. [In Ukrainian]

Gumeniuk MI, Denysova OV, Gumeniuk GL, Opimakh SG, Ignatieva VI. Decamethoxin: nebulizer therapy of infectious exacerbation of chronic bronchitis. Asthma and allergy [Internet]. Asthma and Allergy; 2019;2019(3):17–28. Available from: https://doi.org/10.31655/2307-3373-2019-3-17-28

Shkurupiy DA, Belyaev IS. Oral remediation is a means of preventing ventilator-associated pneumonia in newborns. Biomedical and biosocial anthropology, 2016;26:143-146. [In Ukrainian]

Dzyublyk OYa., Humeniuk MI, Captain GB, et al. Efficacy and safety of inhaled decamethoxine in the treatment of patients with infectious exacerbation of chronic bronchitis. Asthma and allergies. 2015;(4):22-27. [In Ukrainian]

Panchuk SI, Humeniuk MI, Kovalchuk VP. Antimicrobial activity of decamethoxine against bacterial pathogens of infectious exacerbation of bronchial asthma. Transport medicine of Ukraine. 2014;(1):37-42. [In Ukrainian]

Tsarev AV. Decasan in the prevention and treatment of ventilator-associated pneumonia in patients with polytrauma. Emergency Medicine, 2012; 7-8(46-47):80-84. [In Ukrainian]

Kovalenko SV Experience of using nebulizer therapy with decasan in patients with infectious exacerbation of chronic obstructive pulmonary disease in the pulmonology department [Dosvid zastosuvannia nebulaizernoi terapii dekasanom khvorykh z infektsiinym zahostrenniam khronichnoho obstruktyvnoho zakhvoriuvannia lehen v umovakh pulmonolohichnoho viddilennia]. Ukr. Chemotherapeutic Journal, 2010;1(2):65-66. [In Ukrainian]

Makarov VV. Application of antiseptic "Dekasana" in the treatment of acute lung abscesses [Primenenie antiseptika «Dekasana» v lechenii ostryh abscessov legkih]. Problems of modern thoracic surgery: Proceedings and abstracts of the scientific-practical conference. Simeiz-Kryvyi Rih, 2005:149-153. [In Russian]

Shandala MG. Current state and possible prospects for solving the problem of virulence testing of disinfectants [Sovremennoe sostoyanie i vozmozhnye perspektivy resheniya problemy testirovaniya virulicidnosti dezinficiruyushchih sredstv]. Epidemiology and Infectious Diseases, 2005:2:42-43. [In Russian]

Dzyublyk IV, Dzyublyk YaA, Yachnyk VA, et al. Methods of prevention of coronavirus infection with decamethoxine in adults (information letter – emergency. Kyiv, 2020. [In Ukrainian]

Клінічний погляд на можливість і доцільність застосування декаметоксину в період інфекційної пандемії COVID 19



How to Cite

Halushko O. A clinical view on the possibility and feasibility of using decamethoxin during the COVID-19 pandemic. prmd [Internet]. 2021 May 21 [cited 2021 Sep. 27];4(1):30-8. Available from: https://perioperative.org.ua/index.php/prtmdc/article/view/57



Clinical thinking

Most read articles by the same author(s)